Foreigners' 6 Trillion Won Net Selling, Liquidity Seems to Have a Problem | Hong Sun-ae, Writer Jang Woo-jin

[단독 인터뷰] 외국인 6조 원 순매도, 유동성에 문제가 생긴 것 같습니다 | 홍선애, 장우진 작가 [여의도 인사이트]
Watch on YouTube ↗  |  February 05, 2026 at 08:48  |  52:09  |  3PRO TV (삼프로TV)
Speakers
Jang Woo-jin — Writer

Summary

Jang Woo-jin argues that the Korean market selloff is primarily driven by FX and liquidity: a U.S. strong-dollar stance and Treasury funding needs are pulling capital to the U.S., pressuring the won and risk assets. He recommends holding at least 30% cash, avoiding Bitcoin, MSTR, and weak gold/silver, while using dips to position in Korean cosmetics and inbound demand, KOSDAQ policy beneficiaries, semiconductors and AI hardware, and select names like APR, Celltrion, and KakaoBank. He sees near-term volatility but expects Korean policy support through the June local elections.

  • Jang Woo-jin attributes the Korean market drop mainly to FX and liquidity, with a U.S. strong-dollar policy pulling capital into dollar assets.
  • Foreigners sold a record 6 trillion won while individuals bought 9.5 trillion won; he recommends raising cash to at least 30%.
  • Bitcoin, MSTR, and gold/silver are weak, reinforcing liquidity stress, while the dollar and Treasuries attract flows.
  • Korean sector rotation favors cosmetics and inbound demand, with APR showing strong U.S. and Japan growth; defense and shipbuilding face valuation pressure.
  • Solar is active but binary on the space theme; KOSDAQ biotech needs individual stock selection, while Celltrion has its own PBM-reform angle.
  • Policy expectations before June local elections could support Korean equities and especially KOSDAQ after a correction.
  • Semiconductors and AI hardware remain favored on dips, though near-term fear persists until Nvidia earnings and China memory expansion is a longer-term risk.
Ideas
Strong dollar policy pressures won.
Bessent's shift to a strong-dollar stance and refusal to intervene for foreign currencies are aimed at stabilizing long-term Treasury issuance; with about $530 billion of Q1 Treasury funding needed, the U.S. wants the dollar strong and capital flowing into Treasuries, pressuring the won and keeping USD/KRW and the dollar index elevated.
Bitcoin remains vulnerable to liquidity drain.
Bitcoin's sharp drop toward $70k while gold and silver also fell suggests real liquidity stress, not just rotation; Michael Burry warns of a staged collapse, leveraged holders like MSTR may be forced to sell, and the U.S. government says it will not buy BTC strategically, so no bottom signal is visible.
Gold and silver rebound too weak.
Gold and silver failed to rebound strongly from their sharp selloffs, and their renewed plunge despite geopolitical risk points to broad liquidity withdrawal rather than safe-haven demand; the speaker sees no need to bet on them now.
Buy AI hardware dips despite fear.
The speaker is not worried about AI hardware fundamentals; massive capex such as Alphabet's $175-185 billion plan supports demand, so hardware dips are opportunities, though near-term fear may persist until Nvidia's earnings.
Raise cash to 30% for volatility.
Because FX-driven liquidity withdrawal and the reversal of foreign/individual flows create elevated volatility, the speaker advises raising cash to at least 30% rather than fully selling, so investors can act calmly and buy opportunities if the market falls.
US equities may outperform Korea short-term.
Near-term, capital is being pulled into the U.S. by the strong-dollar policy and Treasury issuance, so U.S. equity returns may temporarily outperform Korea even though the speaker is not bearish on the whole global market.
US money rotates into value stocks.
U.S. portfolio flows are rotating out of tech/AI into value stocks and companies without AI controversy but with solid earnings; this rotation can favor U.S. value.
Apple benefits as AI-excluded quality name.
Apple is strong despite being considered an AI laggard because investors are favoring quality companies with solid earnings and no AI controversy; Apple is a key beneficiary of that rotation.
Korean cosmetics gain on China inbound.
Korean cosmetics and inbound-demand sectors are improving with expectations of record Chinese tourist arrivals during Lunar New Year; as the sales numbers show up, the market may re-rate the sector strongly, and the small sector can move sharply when money rotates from large caps.
Defense valuations fall on weak results.
Korean defense stocks had run up on high expectations, but Hyundai Rotem's earnings disappointed; without new momentum, valuations should compress.
Shipbuilders lack new momentum.
Shipbuilders' earnings are not bad, but there is no new momentum, so their valuation and re-rating levels are falling.
MSTR's leveraged Bitcoin strategy unwinds.
MicroStrategy's model of issuing equity and debt to buy Bitcoin worked while its equity premium over BTC rose; if Bitcoin keeps falling, that premium can invert and the company may have to sell BTC to defend its value, creating reflexive downside.
Korean market supported until June elections.
Although near-term FX and liquidity risk warrants higher cash, the speaker expects the Korean market to remain supported by government stimulus before the June local elections, making selloffs opportunities.
Korean solar needs space theme.
Korean solar stocks have turned up, but they surged 30-50% in two days and are now tied to the space theme; the rally can continue only if the space theme stays alive, so it is a watch rather than a clean long.
US solar wins from China cuts.
China's anti-involution policy is cutting polysilicon capacity and raising solar input prices, while the U.S. has blocked Chinese and Southeast Asian solar imports; U.S. manufacturers and companies able to export to the U.S. are the beneficiaries.
APR grows rapidly in US, Japan.
APR's Q4 revenue more than doubled with U.S. sales up 270% and Japan up 289%; analysts broadly raised targets, and Ulta Beauty plus Europe provide further upside, making it a favored Korean cosmetics name.
Small-cap reports drive Korean stock pops.
With abundant money and large caps stalled, Korean investors are increasingly chasing analyst reports; small-cap analyst coverage is moving prices, so less-covered small caps can spike on credible reports.
Celltrion gains from PBM reform.
Celltrion's earnings are good, and its biosimilar and CDMO business should benefit from U.S. PBM reform favoring biosimilars, giving it separate positive momentum from the weak KOSDAQ biotech group.
KOSDAQ biotech lacks sector momentum.
KOSDAQ biotech is no longer a group rally: Alteogen's earnings missed, ABL Bio's clinical timeline slipped, and until new global deals or clinical catalysts appear, sector momentum is weak and stock picking is required.
Policy support lifts KOSDAQ after correction.
Before the June local elections, the government is likely to announce strong KOSDAQ support policies, including separate KOSPI and KOSDAQ supervision and higher pension allocations; after a correction, money can rotate quickly into KOSDAQ and push it above 1300.
KakaoBank funding-cost gain, mixed momentum.
KakaoBank's NIM recovery lifted interest income, and its capital-company acquisition should lower funding costs by using KakaoBank's credit; however, earnings alone imply bank-like valuation and KB also did well, so momentum is mixed.
Up Next

This 3PRO TV (삼프로TV) video, published February 05, 2026, features Jang Woo-jin discussing USD/KRW, DXY, BTC, GLD, SILVER, SMH, CASH, SPY, VTV, AAPL, Korean cosmetics, Korean inbound tourism, Korean defense stocks, 064350.KS, Korean Shipbuilding Stocks, MSTR, Korean equities, Korean solar stocks, US-exposed solar companies, 278470.KS, Korean small-cap equities, 068270.KS, Korean KOSDAQ biotech, KOSDAQ, 323410.KS. 21 trade ideas extracted by AI with direction and confidence scoring.

Speakers: Jang Woo-jin  · Tickers: USD/KRW, DXY, BTC, GLD, SILVER, SMH, CASH, SPY, VTV, AAPL, Korean cosmetics, Korean inbound tourism, Korean defense stocks, 064350.KS, Korean Shipbuilding Stocks, MSTR, Korean equities, Korean solar stocks, US-exposed solar companies, 278470.KS, Korean small-cap equities, 068270.KS, Korean KOSDAQ biotech, KOSDAQ, 323410.KS